NCT05062525View on ClinicalTrials.gov

Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients

CompletedOBSERVATIONAL
Enrollment

53

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
COVID-19Cancer
Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT05062525 - Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients | Biotech Hunter | Biotech Hunter